MEKICS CO., Ltd
Financials
Valuation Metrics
MEKICS CO., Ltd's Market Cap is ₩225B. At end of 2025 it was ₩306B. Ranked #2215 of 2,410 in KR market (top 92%), #1454 of 1,631 on KOSDAQ (top 89%), #91 of 94 in Health Care Equipment & Services (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.46B KRW | KR#2,215/2,410 Sec#91/94 |
| Revenue | 13.76B KRW | KR#2,226/2,410 Sec#77/94 |
| Net Income | 1.08B KRW | KR#1,474/2,410 Sec#47/94 |
| Total Assets | 56.48B KRW | KR#2,143/2,410 Sec#70/94 |
| Net Assets | 37.41B KRW | KR#2,086/2,410 Sec#73/94 |
| Employees | 106 | KR#1,598/2,410 Sec#55/94 |
| Value | ||
| P/E | 20.83x | KR#1,220/2,410 Sec#38/94 |
| P/B | 0.60x | KR#1,063/2,410 Sec#18/94 |
| P/S | 1.63x | KR#1,748/2,410 Sec#45/94 |
| EV/EBITDA | 67.11x | KR#1,430/2,410 Sec#47/94 |
| FCF Yield | -11.40% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | 2.88% | KR#1,337/2,410 Sec#46/94 |
| ROA | 1.91% | KR#1,236/2,410 Sec#46/94 |
| Op. Margin | 3.71% | KR#1,134/2,410 Sec#42/94 |
| Revenue Growth | 30.23% | KR#390/2,410 Sec#20/94 |
| Financial Health | ||
| Debt Ratio | 50.99% | KR#971/2,410 Sec#56/94 |
| Total Debt | 15.31B KRW | KR#1,485/2,410 Sec#45/94 |
| FCF | -2.56B KRW | KR#1,367/2,410 Sec#44/94 |
| Cash | 3.54B KRW | KR#2,122/2,410 Sec#84/94 |
| Current Ratio | 1.23x | KR#1,470/2,410 Sec#73/94 |
| Net Debt/EBITDA | 23.07x | KR#1,393/2,410 Sec#45/94 |
| Dividend | ||
| Div. Growth | -63.86% | KR—/2,410 Sec—/94 |
| Performance | ||
| 1Y Return | -22.26% | KR#1,235/2,410 Sec#37/94 |
| 1M Return | -7.74% | KR#764/2,410 Sec#27/94 |
| From 52W High | -65.42% | KR#1,899/2,410 Sec#72/94 |
| 1Y MDD | -60.49% | KR#1,469/2,410 Sec#49/94 |
| Trading | ||
| Volume | 11,085 shares | KR#1,391/2,410 Sec#59/94 |
| Trading Value | 15.3M KRW | KR#1,879/2,410 Sec#76/94 |
| Foreign Own. | 5.45% | KR#801/2,410 Sec#24/94 |
| Per Share | ||
| EPS | 66 KRW | KR#1,485/2,410 Sec#46/94 |
| BPS | 2,304 KRW | KR#2,013/2,410 Sec#66/94 |
Company Info
Mecics, established in 1998 and listed on KOSDAQ in 2015, designs, manufactures, and sells medical devices such as artificial respirators, respiratory therapy devices, and patient monitoring devices for emergency rooms and intensive care units. The company developed Korea's first artificial respirator, securing international competitiveness. It leads the global market with world-class high-flow respiratory therapy technology and is expanding sales following US FDA approval and Japan PMDA registration. Mecics was established in 1998 and is headquartered in Paju, Gyeonggi-do.